Investigations of the levels of relevant biomarkers such as plasma glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated-tau181 (p-tau181) have been widely used to distinguish AD stages [4, 5]. The gene discussed is GFAP; the disease is Alzheimer disease.